Tool Guides Duration of Dual Antiplatelet Therapy After PCI

This article originally appeared here.
Share this content:
Tool Guides Duration of Dual Antiplatelet Therapy After PCI
Tool Guides Duration of Dual Antiplatelet Therapy After PCI

WEDNESDAY, March 30, 2016 (HealthDay News) -- A new prediction rule may inform which patients will see a benefit or harm from dual antiplatelet therapy beyond one year after percutaneous coronary intervention (PCI), according to a study published online March 29 in the Journal of the American Medical Association.

Robert W. Yeh, M.D., from the Beth Israel Deaconess Medical Center in Boston, and colleagues developed a clinical decision tool to identify patients expected to derive benefit versus harm from continuing thienopyridine beyond one year after PCI. The tool was based on stratification of patients participating in the DAPT (Dual Antiplatelet Therapy) study and was validated on patients in the PROTECT (Patient-Related Outcomes With Endeavor versus Cypher Stenting) trial.

The researchers found that continued thienopyridine versus placebo was associated with reduced ischemic events (P < 0.001) in the high-score group (score ≥2; 5,917 patients) compared with the low-score group (score <2, 5,731 patients; P = 0.07; interaction P < 0.001). Conversely, in the high-score group, continued thienopyridine was associated with smaller increases in bleeding (P = 0.26) compared with the low-score group (P < 0.001; interaction P = 0.02). However, among PROTECT patients in the validation cohort, the high-score patients (2,848) had increased ischemic events compared with the low-score patients, and no significant difference in bleeding.

"Among patients not sustaining major bleeding or ischemic events one year after PCI, a prediction rule assessing late ischemic and bleeding risks to inform dual antiplatelet therapy duration showed modest accuracy in derivation and validation cohorts," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »